News

Clinical Trial Transparency: A Reassessment of Industry Compliance With Clinical Trial Registration and Reporting Requirements in the United States

Scott Lassman co-authored the article, "Clinical Trial Transparency: a Reassessment of Industry Compliance With Clinical Trial Registration and Reporting Requirements in the United States," BMJ Open, Volume 7, Issue 9 (2017). The article analyzes compliance with clinical trial disclosure laws in the U.S.

Categories: Publications

Criticism of FDA Citizen Petitions is Often Misguided

Scott Lassman evaluates criticism of the FDA citizen petition process in his article, "Criticism of FDA Citizen Petitions is Often Misguided," Law360, November 20, 2017.

Categories: Publications

Navigating the Approval Process for Drugs and Biologics

Scott Lassman spoke on the FDA approval process for drugs and biologics at ACI's FDA Boot Camp in Boston.

Categories: Speaking

Chambers USA Recognizes Scott Lassman for Work in Pharmaceutical/Medical Products Regulatory Law

Chambers USA: America’s Leading Lawyers for Business has recognized Scott Lassman for his work in Pharmaceutical/Medical Products Regulatory law.

The Chambers rankings are determined by independent research into a range of qualities and evidence of an attorney's work.

Categories: Honors

Navigating the Approval Process for Drugs and Biologics

Scott Lassman spoke on the FDA approval process for drugs and biologics at ACI's FDA Boot Camp in New York, NY.

Categories: Speaking

2016 All Hands Meeting: FDA Update

Scott Lassman spoke on FDA developments at the 2016 All Hands Meeting for the Life Sciences track in Santa Clara, CA.

Categories: Speaking

The New Drug Approval Process

Scott Lassman was a speaker on the panel "The New Drug Approval Process: Basic Concepts" at FDLI’s Introduction to Drug Law Course.

Categories: Speaking

Scott Lassman

Scott M. Lassman's Profile Image
Scott Lassman has nearly 30 years’ experience in FDA law and policy, both as an in-house attorney and in private practice. He provides strategic advice and advocacy to small, mid-size and large pharmaceutical, biotechnology and medical device companies, as well as the trade associations that represent them and the investors who fund them. His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval and policy matters...

Read More About Scott

For More Information

  • This field is for validation purposes and should be left unchanged.